Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: a longitudinal study of blood coagulation and fibrinolysis.
Potential effects of tamoxifen therapy on blood coagulation and fibrinolysis were investigated in women with breast cancer. We studied 14 parameters of hemostasis in 19 postmenopausal women receiving 20 mg tamoxifen/day as an adjuvant treatment. Blood sampling was done before and after the 1st, 3rd, and 6th month of treatment. Pretreatment values of procoagulation, anticoagulation, plasminogen, and plasminogen activator inhibitor were found within the reference range, whereas tissue-plasminogen activator, fibrin degradation products, and prothrombin-fragment 1+2 were elevated. On therapy an initial decrease of all measured parameters was observed. The effect was pronounced in coagulation inhibitors (antithrombin III, protein C and S). No pathological values (below 60%) were observed. No further effects were found during the 3rd and 6th month of treatment. Our data indicate that the decrease of hemostatic parameters during the initial phase of tamoxifen treatment is due to the timing of blood collection, which took place no more than 14 days after surgery. The reduction of coagulation inhibitors was not associated with pathological values. No cumulative effects were seen during tamoxifen therapy. The decrease was not associated with a concomittant increase of in vivo coagulation markers (prothrombin-fragment 1+2, thrombin-antithrombin-complex, fibrin degradation products). Therefore our results are likely to reflect only the resolution of postoperative activation and do not translate into a drug related thrombogenic effect.
Oberhoff
C
C
Center of Gynecology and Obstetrics, University Hospital Essen, Germany. carsten.oberhoff@uni-essen.de
Szymeczek
J
J
Hoffmann
O
O
Winkler
U H
UH
Kaiser
S
S
Schindler
A E
AE
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001777:Blood Coagulation / Q000187:drug effects*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D004965:Estrogen Antagonists / Q000009:adverse effects*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D008137:Longitudinal Studies; D008875:Middle Aged; D017698:Postmenopause; D013629:Tamoxifen / Q000009:adverse effects*; D013927:Thrombosis / Q000139:chemically induced*
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen